Advertisement

Topics

FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors

01:00 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children – Genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

Other Sources for this Article

Genentech
Media Contact
Liz Walmsley, 650-467-6800
or
Advocacy Contact
Sonali Chopra, 650-467-0842
or
Investor Contacts
Neera Dahiya Ravindran, M.D., 650-491-5281
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...